tiprankstipranks
Moleculin Biotech Advances Annamycin for AML Treatment
PremiumCompany AnnouncementsMoleculin Biotech Advances Annamycin for AML Treatment
1M ago
Moleculin Biotech announces new findings on Annamycin
Premium
The Fly
Moleculin Biotech announces new findings on Annamycin
1M ago
Moleculin Biotech Unveils New Corporate Presentation
Premium
Company Announcements
Moleculin Biotech Unveils New Corporate Presentation
1M ago
Moleculin Biotech’s Phase 3 trial of Annamycin approved by Review Board
PremiumThe FlyMoleculin Biotech’s Phase 3 trial of Annamycin approved by Review Board
1M ago
Moleculin Biotech price target lowered to $8 from $20 at Maxim
Premium
The Fly
Moleculin Biotech price target lowered to $8 from $20 at Maxim
1M ago
Moleculin Biotech Reports Financial Highlights and Future Plans
Premium
Company Announcements
Moleculin Biotech Reports Financial Highlights and Future Plans
1M ago
Moleculin Biotech Highlights Annamycin’s AML Treatment Potential
PremiumCompany AnnouncementsMoleculin Biotech Highlights Annamycin’s AML Treatment Potential
2M ago
Moleculin Biotech to host conference call
Premium
The Fly
Moleculin Biotech to host conference call
2M ago
Moleculin Biotech Hosts Virtual AML KOL Event and Trial Update
Premium
Company Announcements
Moleculin Biotech Hosts Virtual AML KOL Event and Trial Update
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100